Pfizer is ending research for drugs to treat Alzheimer's and Parkinson's
Pfizer will no longer conduct research and development into finding new drugs to treat Alzheimer's and Parkinson's diseases.
The pharmaceutical company made the announcement on Saturday, and it estimates it will cut 300 jobs from its neuroscience discovery and early development programs, Reuters reports. Pfizer, along with GlaxoSmithKline and Eli Lilly, is part of the Dementia Discovery Fund; in 2012, it saw its drug bapineuzumab, made in partnership with Johnson & Johnson for people with mild to moderate Alzheimer's, fail in the second round of clinical trials.
Pfizer said it is redistributing the money it spends on research and is not changing the research and development funding for Lyrica, used to treat fibromyalgia, and tanezumab, marketed as a treatment for joint pain caused by osteoarthritis.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Catherine Garcia has worked as a senior writer at The Week since 2014. Her writing and reporting have appeared in Entertainment Weekly, The New York Times, Wirecutter, NBC News and "The Book of Jezebel," among others. She's a graduate of the University of Redlands and the Columbia University Graduate School of Journalism.
-
Political cartoons for November 27Cartoons Thursday's political cartoons include giving thanks, speaking American, and more
-
We Did OK, Kid: Anthony Hopkins’ candid memoir is a ‘page-turner’The Week Recommends The 87-year-old recounts his journey from ‘hopeless’ student to Oscar-winning actor
-
The Mushroom Tapes: a compelling deep dive into the trial that gripped AustraliaThe Week Recommends Acclaimed authors team up for a ‘sensitive and insightful’ examination of what led a seemingly ordinary woman to poison four people
-
US mints final penny after 232-year runSpeed Read Production of the one-cent coin has ended
-
Warner Bros. explores sale amid Paramount bidsSpeed Read The media giant, home to HBO and DC Studios, has received interest from multiple buying parties
-
Gold tops $4K per ounce, signaling financial uneaseSpeed Read Investors are worried about President Donald Trump’s trade war
-
Electronic Arts to go private in record $55B dealspeed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’
-
New York court tosses Trump's $500M fraud fineSpeed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in IntelSpeed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to ChinaSpeed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with DisneySpeed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
